• No deterioration of subject performance status. • Does not delay imminent intervention to prevent serious complications of disease progression (e.g., CNS metastases). Visits and study examinations will be performed per the Schedule of Assessments. Safety will be assessed by frequency of treatment -emergent adverse events ( TEAEs), evaluation of clinical laboratory parameters (hematology, and biochemistry), weight, vital signs, electrocardiogram (ECG), performance status, physical exams (PEs), and recording of concurrent illness/therapy and a dverse events. CTCAE version 5 will be used to grade all toxicities. All patients will also be monitored for extensive safety assessment including serum cytokines/chemokines, immune reactivation response to HS -110 CTA and immune phenotype profiling of immune cell subsets . A post - treatment safety visit will be conducted approximately 30 days following the last dose. Response to treatment will be assessed according to RECIST 1.11 with planned evaluation performed every 8-week s ± 1-week. Number of patients: 13-30 patients will be enrolled in the study. Based on response observed in patients at different dose levels and/or in patients with a particular tumor type, the study protocol may be amended to allow for cohort expansion of patients with specific characteristics. Diagnosis and main criteria for inclusion: Inclusion Criteria : Patients must meet all of the following inclusion criteria before they wil l be allowed to participate in the trial: 1. Patients with metastatic or advanced, unresectable solid tumor who have progressed, or recurred following standard -of-care (S OC) therapies or are ineligible for, or refuse, safe and effective S OC therapies and f or whom, in the opinion of the I nvestigator, exp erimental therapy with HS-130/HS -110 may be beneficial. 2.